Efficacy and adverse effects of an LMWH (enoxaparin) administered for thrombosis prophylaxis in 38 pregnancies of 35 women with high risk for venous thrombosis were studied. Enoxaparin was used in 20 women with missed abortion prior to emptying the uterus, in one woman before cerclage and in 6 women before caesarean section. In addition it was used for prophylaxis in 11 pregnancies in 8 thrombophilic patients. No increased blood loss was observed during abortion, delivery and caesarean section. No adverse effects were noted. No postoperative thrombosis occured. Out of the 11 pregnancies with thrombophilia one woman has had thrombosis. It occured at the 26th gestational week while using 20 mg of enoxaparin daily. Fetal outcome in pregnancies of thrombophilic patients improved during treatment. Placental infarcts in patients with antiphospholipid antibodies were however, visible even after using 20, 40 and 60 mg of enoxaparin daily. Data suggest that a daily dose of 20-40 mg of enoxaparin is effective and safe for preventing postoperative thrombosis, however, a higher dose seems to be required for prevention of venous and placental thromboses in women with antiphospholipid antibodies.
|Number of pages||6|
|Journal||Magyar Noorvosok Lapja|
|Publication status||Published - Jan 1 1999|
ASJC Scopus subject areas
- Reproductive Medicine
- Obstetrics and Gynaecology